CTLA4 and neoplasm: Immune checkpoint inhibitors (ICIs) such as anti-programmed cell death 1 receptor (anti-PD1) and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) fail to elicit effective anti-tumour responses in the vast majority of CRC patients.